← back to search

Ian F. Tannock

Princess Margaret Cancer Centre · CA
Area of research
Pulmonary and Respiratory Medicine · Statistics and Probability
Research interest
Research interests include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Statistical Methods in Clinical Trials, and Cancer-related cognitive impairment studies.
h-index
111
citations
62,449
works
617
NIH funding
primary concept
Medicine
email

Recent publications

Value, Access, and High-Quality Medical Oncology Care: Can We Have It All?
2026cited by 0position: contributordoi
Conflict of Interest: Moving From Disclosure to Avoidance.
2026cited by 0position: contributordoi
Mapping Radiotherapy Resources for Prostate Cancer Trials in Nigeria: A STAMPEDE 2-Site Survey.
2026cited by 0position: contributordoi
Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials
The Lancet Oncology 2025cited by 34position: lastdoi
Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor.
2025cited by 11position: contributordoi
Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology.
2025cited by 0position: contributordoi
The Lancet Commission on prostate cancer: planning for the surge in cases
The Lancet 2024cited by 607position: middledoi
Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review.
2024cited by 7position: contributordoi
Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending.
2024cited by 2position: contributordoi
Reply to D.J. Stewart et al.
2024cited by 0position: contributordoi
Review of: "On the Need for Better Information from Randomized Clinical Trials in Oncology"
2024cited by 0position: contributordoi
Common Sense Oncology: outcomes that matter
The Lancet Oncology 2023cited by 99position: middledoi
Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs.
2023cited by 49position: contributordoi
Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?
2023cited by 14position: contributordoi
Priorities for cancer research in low- and middle-income countries: a global perspective
Nature Medicine 2022cited by 391position: middledoi
Cognitive impairment in adolescent and young adult cancer patients: Pre‐treatment findings of a longitudinal study
Cancer Medicine 2022cited by 30position: lastdoi
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
2022cited by 4position: contributordoi
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments
Journal of Clinical Oncology 2021cited by 51position: firstdoi
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
Journal of Clinical Oncology 2021cited by 41position: middledoi
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research
The Lancet Oncology 2021cited by 40position: middledoi
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.
2021cited by 39position: contributordoi
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
2021cited by 35position: contributordoi
Should Basket Trials Be Pathways to Drug Registration for Biomarker-Defined Subgroups of Advanced Cancers?
2021cited by 7position: contributordoi
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Journal of Clinical Oncology 2018cited by 122position: middledoi
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
European Urology 2017cited by 641position: middledoi
Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy
Journal of Cancer Survivorship 2017cited by 82position: middledoi
A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer
Brain Imaging and Behavior 2017cited by 76position: lastdoi
Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
Annals of Oncology 2016cited by 87position: middledoi
Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study
Annals of Oncology 2016cited by 76position: lastdoi
Pretreatment Differences in Intraindividual Variability in Reaction Time between Women Diagnosed with Breast Cancer and Healthy Controls
Journal of the International Neuropsychological Society 2016cited by 40position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 15 papers (2021–2026)Gregory R. Pond · Université Claude Bernard Lyon 16 papers (2013–2025)Elizabeth A. Eisenhauer · University of North Texas Health Science Center5 papers (2023–2025)Manju Sengar · Grant Medical Center4 papers (2021–2025)Janette L. Vardy · University of Sydney4 papers (2014–2017)Haryana M. Dhillon · The University of Sydney4 papers (2014–2017)Bishal Gyawali · Clarivate PLC3 papers (2023–2024) · 3 papers (2023–2025)Mario A. Eisenberger · Johns Hopkins Medicine3 papers (2013–2018)Francisco Vera-Badillo · Kingston Health Sciences Centre3 papers (2014–2022)Anna Dodd · Ontario Institute for Cancer Research3 papers (2014–2017)Sean B. Rourke · Toronto Public Health3 papers (2014–2017)Guru Sonpavde · AdventHealth Orlando3 papers (2013–2014)Corrinne Renton · The University of Sydney3 papers (2014–2017)Mark J. Ratain · University of Chicago2 papers (2021–2021)Johann S. de Bono · CRUK Lung Cancer Centre of Excellence2 papers (2015–2018)Stephen Clarke · Carnegie Mellon University2 papers (2014–2016)Soumya Swaminathan · National Tuberculosis Institute2 papers (2021–2022)Bernard L. Marini · American Association of Colleges of Pharmacy2 papers (2023–2025)Michelle Tregear · National Coalition for Cancer Survivorship2 papers (2023–2025)